Carvedilol, CAS# 72956-09-3, is known as the brand name Coreg, which is marketed by GlaxoSmithKline. The patent for Coreg will expire on June 7, 2015, making way for a generic market. As a beta-blocker used to treat hypertension and heart failure, carvedilol is also often prescribed to treat and prevent heart attack symptoms. Carvedilol is also an impressive treatment for patients who have survived a myocardial infarction, and experience a left ventricular dysfunction with an ejection fraction of less than 40 percent. In terms of treating patients with high blood pressure, carvedilol is a sound choice for the management of essential hypertension, and it can be utilized as monotherapy or in conjunction with other antihypertensive agents, such as thiazide-type diuretics.
Individualized dosing is recommended, however, the typical dose for patients with hypertension is the 6.25 milligram tablet, taken twice daily. Once the patient has displayed a tolerability to the lowest dose it is commonly increased to the 12.5 milligram tablet, taken twice daily. One to two weeks normally lapse in between dosage increases to lend enough time for the patient to show a safe, effective and tolerable reaction to this drug. Some patients are eventually dosed to a 25 milligram tablet, also taken twice a day. Patients are not advised to take any more then 50 milligrams daily. Side effects are usually not severe, and may include a decreased sex drive and impotence, insomnia, nervousness and anxiety.
Evaluated for safety in over 2,193 patients in U.S. clinical trials, as well as 2,976 patients in international trials, carvedilol has proven itself to be a strong and dynamic medication. One particular clinical trial, deemed CAPRICORN, compared carvedilol and a placebo for the treatment of patients who had experienced a recent myocardial infarction. This patient population had a documented left ventricular ejection fraction of less then 40 percent, and 47 percent of these patients also exhibited symptoms of heart failure. The CAPRICORN study was a double-blind study, which involved 1.959 patients. Results were outstanding in favor of the patients who received carvedilol, starting with 6.25 milligrams a day and titrated to 25 milligrams twice a day. The mortality risk was a 23 percent reduction in patients treated with carvedilol, and there was an admirable 40% reduction in fatal and non fatal future myocardial infarctions. The Vascular Health and Risk Management posted a report in June of 2012 which enumerated reasons for their support of carvedilol. Specifically they noted that as a noncardioselective third-generation beta-blocker, carvedilol was effective while still being free of negative hemodynamic and metabolic effects, which many traditional beta-bockers have. In addition, when compared with fellow beta-blockers, carvedilol was found to consistently maintain cardiac output and offer a sizable reduction in the risk of hypertension. Patients suffering from various metabolic syndromes or diabetes reported positively with treatment of carvedilol, and exhibited favorable effects which were demonstrated in their metabolic profiles. LGM Pharma is a proud provider of both the API and TEVA API carvedilol, and offers client support throughout the research and development process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.